Researchers have successfully demonstrated how an electronic device implanted directly into the brain can detect, stop and even prevent epileptic seizures.
These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications.
The researchers, from the University of Cambridge, the École Nationale Supérieure des Mines and INSERM in France, implanted the device into the brains of mice, and when the first signals of a seizure were detected, delivered a native brain chemical which stopped the seizure from progressing. The results, reported in the journal Science Advances, could also be applied to other conditions including brain tumours and Parkinson’s disease.
The work represents another advance in the development of soft, flexible electronics that interface well with human tissue. “These thin, organic films do minimal damage in the brain, and their electrical properties are well-suited for these types of applications,” said Professor George Malliaras, the Prince Philip Professor of Technology in Cambridge’s Department of Engineering, who led the research.
While there are many different types of seizures, in most patients with epilepsy, neurons in the brain start firing and signal to neighbouring neurons to fire as well, in a snowball effect that can affect consciousness or motor control. Epilepsy is most commonly treated with anti-epileptic drugs, but these drugs often have serious side effects and they do not prevent seizures in three out of 10 patients.
In the current work, the researchers used a neurotransmitter which acts as the ‘brake’ at the source of the seizure, essentially signalling to the neurons to stop firing and end the seizure. The drug is delivered to the affected region of the brain by a neural probe incorporating a tiny ion pump and electrodes to monitor neural activity.
When the neural signal of a seizure is detected by the electrodes, the ion pump is activated, creating an electric field that moves the drug across an ion exchange membrane and out of the device, a process known as electrophoresis. The amount of drug can be controlled by tuning the strength of the electric field.
“In addition to being able to control exactly when and how much drug is delivered, what is special about this approach is that the drugs come out of the device without any solvent,” said lead author Dr Christopher Proctor, a postdoctoral researcher in the Department of Engineering. “This prevents damage to the surrounding tissue and allows the drugs to interact with the cells immediately outside the device.”
The researchers found that seizures could be prevented with relatively small doses of drug representing less than 1% of the total amount of drug loaded into the device. This means the device should be able to operate for extended periods without needing to be refilled. They also found evidence that the delivered drug, which was in fact a neurotransmitter that is native to the body, was taken up by natural processes in the brain within minutes which, the researchers say, should help reduce side effects from the treatment.
Although early results are promising, the potential treatment would not be available for humans for several years. The researchers next plan to study the longer-term effects of the device in mice.
Malliaras is establishing a new facility at Cambridge which will be able to prototype these specialised devices, which could be used for a range of conditions. Although the device was tested in an animal model of epilepsy, the same technology could potentially be used for other neurological conditions, including the treatment of brain tumours and Parkinson’s disease.
The Latest on: Epilepsy
via Google News
The Latest on: Epilepsy
- Epilepsy Drug Market Global Industry Trends, Share, Size and Forecast Reporton January 19, 2021 at 8:06 am
Epilepsy Drug Market Opportunities, Size, Share, Emerging Trends, Technological Innovation and Forecasts "The report on the global epilepsy drug market provides qualitative and quantitative analysis ...
- Epilepsy Drug Market Share, Historical Growth, Analysis, Opportunities and Forecast To 2025on January 19, 2021 at 5:05 am
The global Epilepsy Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 1.4% in the forecast period of 2020 to 2025 and will expected to reach USD ...
- FDA Grants First Conditional Approval Under Expanded Authority to Control Seizures in Dogs with Idiopathic Epilepsyon January 14, 2021 at 12:08 pm
The U.S. Food and Drug Administration grants first conditional approval under expanded authority to treat dogs with seizures associated with idiopathic epilepsy ...
- UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsyon January 13, 2021 at 10:53 pm
UCB today announced the launch of Nile AI, Inc., a new independent company created to improve care for people living with epilepsy, their caregivers, and healthcare providers (HCPs). Nile was founded ...
- 'Have I been a bad mum?' Mothers reveal their 'guilt' after taking 'poisonous' epilepsy drug during pregnancy that left their children with issues such as deafness and autismon January 13, 2021 at 2:17 am
Viewers of Channel 4's Are Women the Fitter Sex? were left shocked last night after three British mothers discussed the impact an epilepsy drug taken during pregnancy had on their children.
- Camila Coelho On Trying To Get Pregnant With Epilepsy: ‘Sharing My Fears Was The Best Thing I’ve Done’on January 9, 2021 at 4:50 am
Camila Coelho opens up about living with the condition, and her decision to stay on her medication while pregnant.
- Four of 10 most common epilepsy medications increase risk of baby ‘having physical birth defect if taken while pregnant’on January 8, 2021 at 7:04 am
Past mistakes must not be repeated. We know that the consequences of women not knowing information such as this can be devastating,’ says campaigner ...
- Parents of children with severe epilepsy warn cannabis medication stopping after Brexiton January 7, 2021 at 5:16 am
Tannine Clarry, 32, from Suffolk, fears that losing access to the prescription will cost her six-year-old daughter Indie-Rose her independence and set back years of progress.
- Avicanna Advances Pharmaceutical Epilepsy Program With Collaboration With the University Health ...on January 6, 2021 at 4:32 am
The multi-level cannabinoid-based collaboration with leading epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil Research Institute at UHN is also supported by a Mitacs Accelerate ...
- Michael and Lisa Cotton fund epilepsy research projects in honor of daughter Vivianon January 6, 2021 at 4:00 am
Vivian lived 18 months as a 27-week premature baby before her parents, Michael and Lisa Cotton of Grosse Pointe Farms, watched as their daughter succumbed in April 2015 to multiple medical ...
via Bing News